PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLutropin alfa
Lutropin alfa
Luveris, Pergoveris (lutropin alfa) is a protein pharmaceutical. Lutropin alfa was first approved as Luveris on 2000-11-29. It is used to treat female infertility in the USA. It has been approved in Europe to treat female infertility and ovulation induction. The pharmaceutical is active against lutropin-choriogonadotropic hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
therapeuticsD013812
investigative techniquesD008919
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03G: Gonadotropins and other ovulation stimulants
— G03GA: Gonadotropins
— G03GA07: Lutropin alfa
HCPCS
No data
Clinical
Clinical Trials
290 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C61——2——2
HypersensitivityD006967EFO_0003785T78.40——2——2
Assisted reproductive techniquesD027724————1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246EFO_0000545—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLutropin alfa
INNlutropin alfa
Description
Lutropin beta chain precursor (Luteinizing hormone beta subunit) (LSH-beta)
Classification
Protein
Drug classtricyclic compounds; atropine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201419
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID3JGY52XJNA (ChemIDplus, GSRS)
Target
Agency Approved
LHCGR
LHCGR
Organism
Homo sapiens
Gene name
LHCGR
Gene synonyms
LCGR, LGR2, LHRHR
NCBI Gene ID
Protein name
lutropin-choriogonadotropic hormone receptor
Protein synonyms
hypergonadotropic hypogonadism, LHR, LSH-R, Luteinizing hormone receptor, lutropin/choriogonadotropin receptor
Uniprot ID
Mouse ortholog
Lhcgr (16867)
lutropin-choriogonadotropic hormone receptor (P30730)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lutropin alfa
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,349 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
532 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use